HATs Cancer Research Results

HATs, histone acetyltransferases: Click to Expand ⟱
Source:
Type:
Histone acetyltransferases (HATs) are a family of enzymes that play a crucial role in the regulation of gene expression by modifying chromatin structure. HATs transfer acetyl groups to the lysine residues of histone proteins, which are the main components of chromatin. This modification, known as histone acetylation, leads to the relaxation of chromatin structure, allowing for increased access of transcription factors to DNA and promoting gene expression.
HATs is overexpressed in cancers with poor prognosis.
Scientific Papers found: Click to Expand⟱
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
5731- Buty,    The Warburg Effect Dictates the Mechanism of Butyrate Mediated Histone Acetylation and Cell Proliferation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
HDAC↓, Warburg↓, TumCP⇅, HATs↑, BioAv↓, other↝, Risk↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2067- PB,    Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer
- in-vitro, PC, NA
HDAC↓, HATs↑,
3322- SIL,    Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460
HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   lipid-P↓, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 1,   SIRT3↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MEK↓, 1,   MMP↓, 3,   Raf↓, 1,   c-Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 2,   RARβ↑, 1,   SIRT1↓, 2,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 1,   APAF1↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↑, 2,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↑, 2,   DR5↑, 1,   hTERT/TERT↓, 1,   JNK↑, 1,   MAPK↓, 2,   Mcl-1↑, 1,   p27↑, 1,   survivin↓, 2,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

EF-1α↓, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   EZH2↓, 1,   H3↑, 1,   H4↑, 1,   HATs↑, 7,   other↝, 1,  

Protein Folding & ER Stress ⓘ

cl‑CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   LC3II↑, 2,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 2,   cl‑PARP↑, 1,   PCNA↓, 2,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycD1/CCND1↓, 2,   P21?, 1,   P21↑, 1,   p‑RB1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 2,   HDAC↓, 7,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC8↓, 2,   HMTs↑, 1,   IGFBP3↑, 1,   mTOR↓, 1,   mTORC1↓, 1,   Nanog↓, 1,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 2,   SOX2↓, 1,   STAT3↓, 2,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 1,   CD31↓, 1,   CDH1↑, 1,   E-cadherin↑, 2,   FAK↓, 1,   miR-203↑, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 2,   PDGF↓, 1,   SOX4↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP⇅, 1,   TumMeta↓, 2,   uPA↓, 2,   Vim↓, 1,   Zeb1↓, 3,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 3,   VEGF↓, 3,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

NHE1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL2↑, 1,   Inflam↓, 1,   MDSCs↓, 1,   NF-kB↓, 2,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   ChemoSen↑, 1,   Dose↝, 2,   eff↑, 1,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 2,   selectivity↑, 2,   TET2↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   EZH2↓, 1,   hTERT/TERT↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 2,   chemoP↑, 2,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 1,   Risk↓, 1,   toxicity↝, 1,   toxicity∅, 1,  
Total Targets: 154

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Migration ⓘ

TIMP1↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   Inflam↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Functional Outcomes ⓘ

neuroP↑, 1,  
Total Targets: 9

Scientific Paper Hit Count for: HATs, histone acetyltransferases
3 Silymarin (Milk Thistle) silibinin
1 alpha Linolenic acid
1 Butyrate
1 Honokiol
1 Phenylbutyrate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:886  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page